NICE celebrates 10th anniversary amid renal cancer drug controversy.
出版信息
BJU Int. 2009 Apr;103(8):ii-iii. doi: 10.1111/j.1464-410X.2009.08579.x.
Abstract
摘要
相似文献
1
NICE celebrates 10th anniversary amid renal cancer drug controversy.在肾癌药物争议中，英国国家卫生与临床优化研究所庆祝成立10周年。
BJU Int. 2009 Apr;103(8):ii-iii. doi: 10.1111/j.1464-410X.2009.08579.x.
2
The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe?英国国立临床优化研究所转移性肾细胞癌治疗指南的应用：是福是祸？
BJU Int. 2010 Aug;106(4):453-7. doi: 10.1111/j.1464-410X.2010.09466.x. Epub 2010 Jun 22.
3
NICE recommends kidney cancer drug it previously rejected on cost grounds.英国国家卫生与临床优化研究所（NICE）推荐了一种此前因其成本原因而被拒绝的肾癌药物。
BMJ. 2009 Feb 9;338:b499. doi: 10.1136/bmj.b499.
4
Sunitinib in renal-cell carcinoma: expanded indications.舒尼替尼用于肾细胞癌：适应证扩展
Lancet Oncol. 2009 Aug;10(8):740. doi: 10.1016/S1470-2045(09)70185-8. Epub 2009 Jul 15.
5
Drug therapy: Preclinical oncology - reporting transparency needed.药物治疗：临床前肿瘤学——需要报告透明度。
Nat Rev Clin Oncol. 2016 Jan;13(1):8-9. doi: 10.1038/nrclinonc.2015.216. Epub 2015 Dec 15.
6
Temsirolimus for advanced renal-cell carcinoma.替西罗莫司用于晚期肾细胞癌。
N Engl J Med. 2007 Sep 6;357(10):1050; author reply 1050-1. doi: 10.1056/NEJMc071868.
7
A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage.肾细胞癌治疗的新策略：以有限的附带损伤打击多个靶点。
JAMA. 2006 Jun 7;295(21):2537-8. doi: 10.1001/jama.295.21.2537.
8
CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.CCR药物更新：索拉非尼和舒尼替尼用于肾细胞癌
Clin Cancer Res. 2007 Jul 1;13(13):3765-70. doi: 10.1158/1078-0432.CCR-06-2844.
9
New targeted therapy for rare stomach, kidney cancers.针对罕见胃癌和肾癌的新型靶向疗法。
FDA Consum. 2006 May-Jun;40(3):5.
10
Treatment options in metastatic renal carcinoma: an embarrassment of riches.转移性肾癌的治疗选择：选择过多令人为难。
J Clin Oncol. 2006 Jan 1;24(1):1-3. doi: 10.1200/JCO.2005.03.7234. Epub 2005 Dec 5.
Zotero 插件